ROBERT E. JONES, MD
Osteopathic Medicine at Arapeen Dr, Salt Lake City, UT
License number
Utah 328208-1205
Category
Osteopathic Medicine
Type
Endocrinology, Diabetes & Metabolism
Address
Address
615 Arapeen Dr, Salt Lake City, UT 84108
Phone
(801) 581-7761
(801) 213-3800
(801) 213-3800
Personal information
See more information about ROBERT E. JONES at radaris.comName
Address
Phone
502 Southwest St, Logan, UT 84321
5056 Camstone Dr, Salt Lake Cty, UT 84120
Professional information
Robert Alexander Jones, Salt Lake City UT - Agent
Work:
Keller Williams Salt Lake City
Salt Lake City
(801) 930-0650
Salt Lake City
(801) 930-0650
Interests:
real estate, soccer, music, dancing, hiking, camping
About:
Prior to joining Keller Williams Realty, I worked in Marketing for over 15 years and Real Estate is all about marketing. I held positions such as Marketing Manager for the Sundance Film Festival, and the Israel Film Festival in NYC, as well as several Fortune 500 firms as clients.I spent many years in business management, marketing, branding and graphic design; all great experiences that help tremendously with the practice of real estate. I have a BA in International Relations from the University of Utah, where I was also Editor in Chief of the Daily Utah Chronicle. I've had the opportunity to live and work in NYC, Portland, Illinois and Norway.I went into real estate because I’ve always enjoyed all aspects of home ownership: buying, selling, remodeling, decorating, and gardening and helping others do the same.I chose a career at Keller Williams Realty because they have an exceptional customer service track record — having been awarded top honors in JD Powers Associates rankings for real estate customer service 3 years in a row.
Links:
Site
Dr. Robert E Jones, Salt Lake City UT - MD (Doctor of Medicine)
Specialties:
Endocrinology, Diabetes & Metabolism, Endocrinology & Metabolism
Address:
615 S Arapeen Dr SUITE 100, Salt Lake City 84108
(801) 581-7761 (Phone), (801) 587-9607 (Fax)
(801) 581-7761 (Phone), (801) 587-9607 (Fax)
Certifications:
Diabetes, Metabolism & Endocrinology, 1983, Internal Medicine, 1979
Awards:
Healthgrades Honor Roll
Languages:
English
Hospitals:
615 S Arapeen Dr SUITE 100, Salt Lake City 84108
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
University of Utah Health Care
50 North Medical Dr, Salt Lake City 84132
Education:
Medical School
University of Utah
Graduated: 1976
Letterman Army Medical Center
Fitzsimons Army Medical Center
University of Utah
Graduated: 1976
Letterman Army Medical Center
Fitzsimons Army Medical Center
Accountant At Sadler, Gibb &Amp; Associates, Llc
Position:
Accountant at Sadler, Gibb & Associates, LLC
Location:
Greater Salt Lake City Area
Industry:
Accounting
Work:
Sadler, Gibb & Associates, LLC
-
Accountant
Contulakin-G, Analogs Thereof And Uses Therefor
US Patent:
6696408, Feb 24, 2004
Filed:
Jun 29, 2000
Appl. No.:
09/606247
Inventors:
A. Grey Craig - Solana Beach CA
David Griffen - Greenville NC
Baldomero M. Olivera - Salt Lake City UT
Maren Watkins - Salt Lake City UT
David R. Hillyard - Salt Lake City UT
Julita Imperial - Salt Lake City UT
Lourdes J. Cruz - Manila, PH
John D. Wagstaff - Satl Lake City UT
Richard T. Layer - Sandy UT
Robert M. Jones - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
David Griffen - Greenville NC
Baldomero M. Olivera - Salt Lake City UT
Maren Watkins - Salt Lake City UT
David R. Hillyard - Salt Lake City UT
Julita Imperial - Salt Lake City UT
Lourdes J. Cruz - Manila, PH
John D. Wagstaff - Satl Lake City UT
Richard T. Layer - Sandy UT
Robert M. Jones - Salt Lake City UT
R. Tyler McCabe - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A01N 3718
US Classification:
514 2, 514 13, 514 14, 530324, 530325, 530326
Abstract:
The present invention is directed to contulakin-G (which is the native glycosylated peptide), a des-glycosylated contulakin-G (termed Thr -contulakin-G), and derivatives thereof, to a cDNA clone encoding a precursor of this mature peptide and to a precursor peptide. The invention is further directed to the use of this peptide as a therapeutic for anti-seizure, anti-inflammatory, anti-shock, anti-thrombus, hypotensive, analgesia, anti-psychotic, Parkinsons disease, gastrointestinal disorders, depressive states, cognitive dysfunction, anxiety, tardive dyskinesia, drug dependency, panic attack, mania, irritable bowel syndrome, diarrhea, ulcer, GI tumors, Tourettes syndrome, Huntingtons chorea, vascular leakage, anti-arteriosclerosis, vascular and vasodilation disorders, as well as neurological, neuropharmalogical and neuropsychopharmacological disorders.
-Conotoxin Peptides
US Patent:
6797808, Sep 28, 2004
Filed:
Jan 28, 2000
Appl. No.:
09/493795
Inventors:
Maren Watkins - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
David R. Hillyard - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Robert M. Jones - Salt Lake City UT
Baldomero M. Olivera - Salt Lake City UT
David R. Hillyard - Salt Lake City UT
J. Michael McIntosh - Salt Lake City UT
Robert M. Jones - Salt Lake City UT
Assignee:
University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
C07K 700
US Classification:
530326, 530327, 530324, 530855, 514 13, 514 14
Abstract:
The invention relates to relatively short peptides (termed -conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
Muo-Conopeptides And Their Use As Local Anesthetics
US Patent:
2002019, Dec 26, 2002
Filed:
Jul 20, 2001
Appl. No.:
09/908739
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
R. McCabe - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Richard Layer - Sandy UT, US
John Wagstaff - Salt Lake City UT, US
Robert Jones - Salt Lake City UT, US
Assignee:
COGNETIX, INC. - Salt Lake City UT
International Classification:
A61K038/17
US Classification:
514/012000
Abstract:
The present invention is directed to the new O-conopeptides, their coding sequences and their propeptides and to the use of O-conopeptides as a local anesthetic for treating pain. The O-conopeptides have long lasting anesthetic activity and are particularly useful for spinal anesthesia, either administered acutely for post-operative pain or via an intrathecal pump for severe chronic pain situations or for treatment of pain in epithelial tissue.
Apha-Conotoxin Peptides
US Patent:
7279549, Oct 9, 2007
Filed:
Jul 21, 2004
Appl. No.:
10/895372
Inventors:
Maren Watkins - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
David R. Hillyard - Salt Lake City UT, US
J. Michael McIntosh - Salt Lake City UT, US
Robert M. Jones - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
David R. Hillyard - Salt Lake City UT, US
J. Michael McIntosh - Salt Lake City UT, US
Robert M. Jones - Salt Lake City UT, US
Assignee:
The University of Utah Research Foundation - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A61K 38/10, A61K 38/17, C07K 7/08, C07K 714/435
US Classification:
530324, 514 12, 514 14, 530327, 530857
Abstract:
The invention relates to relatively short peptides (termed α-conotoxins herein), about 10-30 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
O-Superfamily Conotoxin Peptides
US Patent:
2002017, Nov 21, 2002
Filed:
Dec 28, 2000
Appl. No.:
09/749637
Inventors:
Baldomero Olivera - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
Richard Layer - Sandy UT, US
Robert Jones - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
David Hillyard - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
Richard Layer - Sandy UT, US
Robert Jones - Salt Lake City UT, US
International Classification:
A01N037/18, A61K038/00, G01N033/53, G01N033/567, C07H021/04, C07K005/00, C07K007/00, C07K016/00, C07K017/00
US Classification:
514/002000, 530/324000, 536/023500, 435/007200
Abstract:
The invention relates to relatively short peptides (termed O-Superfamily conotoxins herein), about 20-40 residues in length, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds.
Conotoxin Peptides
US Patent:
7368432, May 6, 2008
Filed:
Jul 19, 2004
Appl. No.:
10/893300
Inventors:
J. Michael McIntosh - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Lourdes J. Cruz - Sta. Mesa, PH
Gloria P. Corpuz - Miliani HI, US
Robert M. Jones - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US
Baldomero M. Olivera - Salt Lake City UT, US
Lourdes J. Cruz - Sta. Mesa, PH
Gloria P. Corpuz - Miliani HI, US
Robert M. Jones - Salt Lake City UT, US
James E. Garrett - Salt Lake City UT, US
Assignee:
Xenome, Ltd. - Queensland
Cognetix, Inc. - Salt Lake City UT
Cognetix, Inc. - Salt Lake City UT
International Classification:
A61K 38/08, A61K 38/17, C07K 7/06, C07K 14/435
US Classification:
514 15, 514 12, 530857, 530327, 530324
Abstract:
The invention relates to relatively short conotoxin peptides, about 10-20 residues in length as described herein, which are naturally available in minute amounts in the venom of the cone snails or analogous to the naturally available peptides, and which preferably include two disulfide bonds. These conotoxin peptides have analgesic activity and are thus useful for treating or preventing pain.
Mu-Conopeptides
US Patent:
2003005, Mar 13, 2003
Filed:
Jul 23, 2001
Appl. No.:
09/910009
Inventors:
Baldomero Olivera - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Ki-Joon Shon - Shaker Heights OH, US
Richard Jacobsen - San Francisco CA, US
Robert Jones - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Gregory Shen - Salt Lake City UT, US
John Wagstaff - Salt Lake City UT, US
J. McIntosh - Salt Lake City UT, US
James Garrett - Salt Lake City UT, US
Maren Watkins - Salt Lake City UT, US
Lourdes Cruz - Manila, PH
Ki-Joon Shon - Shaker Heights OH, US
Richard Jacobsen - San Francisco CA, US
Robert Jones - Salt Lake City UT, US
G. Cartier - Salt Lake City UT, US
Gregory Shen - Salt Lake City UT, US
John Wagstaff - Salt Lake City UT, US
Assignee:
UNIVERSITY OF UTAH RESEARCH FOUNDATION - Salt Lake City UT
International Classification:
A61K038/17, C07K014/435
US Classification:
514/012000, 530/350000
Abstract:
The present invention is to -conopeptides, derivatives or pharmaceutically acceptable salts thereof. The present invention is further directed to the use of this peptide, derivatives thereof and pharmaceutically acceptable salts thereof for the treatment of disorders associated with voltage-gated sodium channels. Thus, the -conopeptides or derivatives are useful as neuromuscular blocking agents, local anesthetic agents, analgesic agents and neuroprotective agents. The -conopeptides are also useful for treating neuromuscular disorders. The invention is further directed to nucleic acid sequences encoding the -conopeptides and encoding propeptides, as well as the propeptides.